NSCLC with epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase rearrangements, or ROS1 mutations is currently recognized as a negative predictor of immunotherapy efficacy (40, 41). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.